Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
FTRE is expected to report earnings to rise 268.75% to 58 cents per share on August 17
Q2'26
Est.
$0.59
Q1'26
Beat
by $0.11
Q4'25
Missed
by $0.44
Q3'25
Missed
by $0.36
Q2'25
Beat
by $0.11
The last earnings report on May 05 showed earnings per share of 15 cents, beating the estimate of 5 cents. With 476.60K shares outstanding, the current market capitalization sits at 1.47B.